anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a gel agent which is prepared from a drug effective component, namely pilocarpine nitrate for the first time and is used for eyes. The gel agent is applied to the treatment of glaucoma, etc., in ophthalmology. The present invention aims to enhance the bioavailability of the drug effective component, a therapeutic effect and medication safety. In the present invention, the gel for eyes is prepared from pilocarpine nitrate for the first time, and the problems that eye drops are easily diluted by tears and stay for a short time in the eyes, and the therapeutic effect of the administration of the whole body is not ideal are solved. The present invention has the main technological content that a stable water-soluble transparent cream body is prepared from pilocarpine nitrate, carbomer, boracic acid, borax, propanediol and chlorobutanol, and one layer of poromeric reticular membrane is formed at the surface of the eyes after the gel agent is used. The present invention has lasting action.
People with COPD are at higher risk of developing cardiovascular disease (CVD). While exercise training is a potent therapy for CVD, people with COPD have a low tolerance for exercise due to dyspnea and premature muscle fatigue. Thus, there is a need to develop more effective strategies to improve CVD risk in people with COPD. A novel way to reduce blood pressure and enhance arterial health is with passive heat therapy (PHT). An acute 45-min bout of lower limb hot-water immersion has been shown to increase leg blood flow and reduce blood pressure in healthy older adults, suggesting that PHT could have similar hypotensive and anti-atherosclerotic effects as exercise. Augmenting leg blood flow with PHT may also have functional benefits by reducing peripheral muscle fatigue and improving exercise tolerance. No study to date has looked at the acute and chronic hemodynamic and vascular responses to PHT in people with COPD, nor whether it can acutely or chronically improve exercise tolerance.
Store VABYSMO in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake. Keep the sealed tray containing the prefilled syringe or the vial in the original carton to protect from light.

Prior to use, the unopened prefilled syringe or glass vial of VABYSMO may be kept at room temperature, 20°C to 25°C (68°F to 77°F), for up to 24 hours. Ensure that the injection is given immediately after preparation of the dose.
Autism spectrum disorder (ASD) is a clinical syndrome characterized by mindreading deficits, or Theory of Mind deficits. The Reading the Mind in the Eyes task (abbreviated as the Eyes task) was developed to assess the mindreading deficits as a hallmark of social deficits of ASD. This study aims to investigate the ability of reading emotions by the Eyes task in adults with ASD, and examine the gazing pattern and frontal activation during the task. We plan to recruit 50 adults with ASD and 50 typically-developing adults. All the participants will complete clinical measures and the Eyes task. Eye-tracking and frontal activation (measured by functional near-infrared spectroscopy) will be examined during the Eyes task.
Cystinosis is a rare inherited recessive disease belonging to the family of Lysosomal Storage Disorders and is characterized by lysosomal accumulation of cystine in all the cells of the body leading to multi-organ failure. Cystinosis has a devastating impact on the affected individuals, primarily children, and young adults, even with cysteamine treatment. The prevalence of cystinosis is 1 in 100,000 to 1 in 200,000. The gene involved in cystinosis is the gene CTNS that encodes for the transmembrane lysosomal cystine transporter - cystinosin. The current standard of care does not prevent the progression of the disease and significantly impacts the quality of life of patients with cystinosis.

For this study, up to 6 subjects meeting eligibility criteria will be transplanted following a 3-cohort staggered treatment design with 2 subjects per cohort. The first 2 cohorts will consist of 4 adults (18 years or older), potentially followed by a cohort consisting of 2 adolescents or adults (\> 14 years old). Following the informed consent process, enrolled subjects will be screened to confirm full eligibility for participation. Eligible subjects will undergo hematopoietic stem cell (HSC) mobilization and collection (leukapheresis). A portion of cells will be kept as "back-up" for rescue purpose if necessary, and a portion will be ex vivo gene-modified with a lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, to express CTNS gene (product name: CTNS-RD-04). Clinical manufacturing for patients in Cohort 3 will introduce a transduction enhancer LentiBOOST (product name for these patients will be CTNS-RD-04-LB, where the suffix "-LB" stands for LentiBOOST). The subjects will receive marrow cytoreduction with busulfan prior to infusion of CTNS-RD-04. Subjects will discontinue cysteamine treatment during the assessment period. The assessment follow-up period will include an initial 2 years of active end-point evaluations, where the subjects will be evaluated at 3-, 6-, 9-, 12-, 18- and 24-months post-transplantation. A Long-Term Follow-Up study (LTFU) for a total 15-year follow-up period will be offered to all subjects.

The objectives of this Phase 1/2 clinical study are to assess the safety/tolerability of CTNS-RD-04, and its efficacy through a number of clinical, molecular and biochemical assessments.
Rosacea is a chronic inflammatory disorder primarily affecting the facial skin, prominently involving the cheeks, nose, chin, forehead, and periorbital area. Cutaneous manifestations encompass persistent facial erythema, phymas, papules, pustules, telangiectasia, and flushing. The pathogenesis of rosacea is associated with various exacerbating or triggering factors, including microbial infestation, temperature fluctuations, sunlight exposure, physical exertion, emotional stress, consumption of hot beverages and spicy foods, and exposure to airborne pollen. These environmental factors interact with genetic predispositions in the development of rosacea. The roles of the lipophilic microbiome, ultraviolet radiation, nociceptive responses, and vascular alterations have been proposed as significant factors in the pathogenesis. These insights contribute to understanding the anatomical specificity of facial involvement and the progressive nature of rosacea. East Asian skin, predominantly classified as Fitzpatrick skin phototypes III to IV, is characterized by relatively diminished skin barrier function and increased sensitivity to irritants. Airborne pollen exposure may particularly act as a trigger in East Asian individuals, possibly mediated through toll-like receptors. The lack of specificity in objective clinical and histopathological findings leads to diagnostic challenges for individuals with colored skin, including East Asians, particularly when erythema is the sole objective manifestation. An alternative diagnostic scheme may thus be necessary. A diagnostic approach emphasizing vascular manifestations and nociceptive symptoms potentially holds promise for individuals with darker skin tones. More research focusing on potential variations in skin physiology across different racial groups is essential to establish more effective diagnostic schemes applicable to both dark and light skin colors.
Patient will receive four cycles of cisplatin (CDDP) 25 mg/mq i.v. and gemcitabine (GEM) 1000 mg/mq i.v. days 1 and 8 every 21 days, plus durvalumab 1120 mg day 1, followed (one week after the last dose of CDDP/GEM) by two administrations of durvalumab i.v. at 1500 mg once every 4 weeks and one administration of tremelimumab i.v. at 300 mg single dose. Premedication with antihistamines at standard doses can be applied.
PROBLEM TO BE SOLVED: To provide a safe agent and cosmetic without no side effects that increase epidermal barrier function and form a healthy epidermis, as well as may form a flexible and stretchable skin by inhibiting aging of dermal fibroblasts; and further to provide an active ingredient that can solve a plurality of skin troubles at once by one ingredient.SOLUTION: The invention relates to a cell differentiation promoter, a barrier function improvement agent, a SA-β-Gal activity inhibitor, a radical scavenging promotor, and a cosmetic containing as an active ingredient a fermentation product obtained by fermenting a root portion of Ixeris dentata, such as Hemerocallis fulva var. kwanso, Hemerocallis fulva, Hemerocallis middendorffii var. esculenta (Hemerocallis middendorffii var. esculenta), Hemerocallis flava var. minor., and Hemerocallis lilioasphodelus L. of Liliaceae Hemerocallis, with lactic acid bacteria. As for the lactic acid bacteria, Lactobacillus plantarum is preferable.
The process of deinstitutionalization has transitioned a large majority of persons with developmental disabilities into the community over the past several decades, and that number will only increase going forward. There are 926 people in this region who are provided assistance through the Division of Mental Retardation Services (DMRS). People with developmental disabilities frequently have comorbidities such as spasticity that hinder their ability to participate in activities of daily living. Spasticity results from brain or spinal cord injury and can produce increased muscle tone, causing joint stiffness, contractures and pain that can interfere with recommended treatment. A previous survey conducted at Clover Bottom Developmental Center investigated care areas typically affected by spasticity, including splinting, hygiene, dressing, transfers, positioning, ambulation, and engaging in other functional activities. Pfister et al. reported the prevalence of spasticity in the developmental center to be 35% (72/205); of those people, the Survey Physician felt that 75% (54/72) would achieve a functional benefit from treatment.

Primary endpoints will assess the prevalence of spasticity in adults who reside in the community, and whether or not spasticity impacts activities of daily living. When appropriate, potential care area goals will be identified, and treatment options will be recorded. Secondary endpoints will examine whether or not participants currently receive treatment for spasticity; if so, what treatment is being used; and which care areas are most impacted by spasticity.
Nonhuman primates are widely used in transplantation research as preclinical xeno- or allo-transplantation models. Rabbit anti-thymoglobulin (ATG) is often used for T-cell depletion as an immunosuppressant. T-cell depletion can cause a secondary cytokine storm syndrome that can be minimized/prevented by a prophylactic administration of systemic corticosteroids and antihistamines. We report a case of death due to CSS in a cynomolgus monkey with follicular hyperplasia-induced systemic lymphadenopathy after ATG administration. A 6-year-old female cynomolgus monkey was rendered diabetic and then transplanted with a genetically modified porcine pancreatic islets (PPI) (50 000 IEQ/kg) through the portal vein 22 days later without immunosuppressant. Because graft function was not comparable, we planned re-transplantation of PPI. For re-transplantation of the PPI, we performed an intravenous (IV) ATG infusion for inductive immunosuppression. The monkey died 3 h and 30 min after ATG administration despite cardiopulmonary resuscitation. Systemic lymphadenopathy was observed on submandibular, axillary, inguinal, foregut, colic, and hilar lymph nodes, and splenomegaly was also observed on necropsy. Histopathologic examination of the lymph node revealed follicular hyperplasia. The IL-6 level was higher after ATG infusion compared to before ATG infusion (before vs. after ATG infusion; 14.9 vs. >5000 pg/mL). The death of the cynomolgus monkey was caused by severe CSS because of apoptosis of B cells in the systemic lymph nodes caused by the ATG administration. A thorough physical examination of palpable lymph nodes and pre-ATG sonographic or computed tomographic screening could have identified lymphadenopathy, potentially preventing its infusion and reducing mortality risk.
Traditional technique vs CompuFlo use: Using the traditional technique (loss-of-resistance technique), the epidural needle is advanced through the subcutaneous tissues with the needle stylet in place until the needle tip is positioned in the interspinous ligament-this is noted by the proceduralist by an increase in tissue resistance (attempted injection into ligamentous tissue is met with high resistance). The stylet or introducer is removed, and a ground-glass syringe filled with 2-3 mL of saline with an air bubble is attached to the hub of the epidural needle. If the tip of the needle is within the ligament, gentle attempts at injection are met with resistance, and injection of the saline is not possible. The needle is then slowly advanced, millimeter by millimeter, with either continuous or rapidly repeating attempts at injection. As the tip of the needle enters the posterior epidural space, a sudden loss of resistance is noted, and the saline injects easily. Once the needle tip is in the epidural space, the epidural catheter is threaded through the needle and the needle is removed, leaving the catheter sited in the epidural space.

The CompuFlo technique complements this basic technique. Similar to the traditional technique, the needle is advanced through the subcutaneous tissues with the stylet in place until the interspinous ligament is entered, as noted by an increase in tissue resistance. After removing the stylet, flexible tubing from the CompuFlo disposable tubing-syringe set is attached to the hub of the needle instead of the traditional ground-glass syringe. The fluid-filled syringe is placed in the CompuFlo device. The needle is then advanced continuously with the device electronically sensing pressure in real time, providing a numerical value (100 to 150 mm Hg) on the read-out screen. As the tip of the needle enters the posterior epidural space, a sudden loss of resistance (associated with a significant loss of pressure to less than 50 mm Hg or 50% of the starting pressure) is noted. The pressure drop needs to be sustained for at least 5 seconds. An audio signal also signals the acute change in pressure.
Heart Failure can cause physical disability and death. According to the Ministry of Health and Welfare, there were 20,644 deaths from heart disease, ranking second among the top 10 causes of death \[1\]. The World Health Organization (WHO) has advocated nursing guidance with the concept of "empowerment", where patients can play an active and aggressive role in managing their health \[2\]. This paperless nursing health education guidance information can be designed through the application, which features non-professional expressions and visualization methods. The users can participate in feedback-based interactions and complete the questionnaires after receiving nursing guidance. This study used the Technology Acceptance Model (TAM) to evaluate patients' acceptance of the nursing guidance application and the effectiveness of such nursing guidance.
The invention discloses application of a compound in preparation of a SARS-Cov-2E protein inhibitor. In a first aspect of the application, there is provided the use of a compound, or a pharmaceutically acceptable salt thereof, of formula a-L-B; the product has at least one function of a 1-a 3: a1. inhibiting the ion channel activity of SARS-Cov-2E protein; a2. reducing the pathogenicity of SARS-Cov-2; a3. preventing and/or treating novel coronavirus pneumonia caused by SARS-Cov-2. According to the application of the embodiment of the application, at least the following beneficial effects are achieved: the applicant finds in the experimental process that the compound with the structure or the pharmaceutically acceptable salt thereof has good effect on inhibiting the activity of an ion channel of SARS-Cov-2E protein, and thus the compound can be used for preparing products with corresponding functions.
Amiloride HCl is a potassium-conserving (antikaliuretic) drug that possesses weak (compared with thiazide diuretics) natriuretic, diuretic, and antihypertensive activity. These effects have been partially additive to the effects of thiazide diuretics in some clinical studies. When administered with a thiazide or loop diuretic, amiloride has been shown to decrease the enhanced urinary excretion of magnesium which occurs when a thiazide or loop diuretic is used alone. Amiloride has potassium-conserving activity in patients receiving kaliureticdiuretic agents.

Amiloride HCl is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone.

Amiloride exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct; this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. This mechanism accounts in large part for the potassium sparing action of amiloride.

Amiloride usually begins to act within 2 hours after an oral dose. Its effect on electrolyte excretion reaches a peak between 6 and 10 hours and lasts about 24 hours. Peak plasma levels are obtained in 3 to 4 hours and the plasma half-life varies from 6 to 9 hours. Effects on electrolytes increase with single doses of amiloride HCl up to approximately 15 mg.

Amiloride HCl is not metabolized by the liver but is excreted unchanged by the kidneys. About 50 percent of a 20 mg dose of amiloride HCl is excreted in the urine and 40 percent in the stool within 72 hours. Amiloride has little effect on glomerular filtration rate or renal blood flow. Because amiloride HCl is not metabolized by the liver, drug accumulation is not anticipated in patients with hepatic dysfunction, but accumulation can occur if the hepatorenal syndrome develops.
BACKGROUND: The risk of incident dementia after surgery in older adults is unclear. The study objective was to examine the rate of incident dementia among older adults after elective surgery compared with a matched nonsurgical control group.
METHODS: We conducted a population-based, propensity-matched retrospective cohort study using data from linked administrative databases in Ontario, Canada. All community-dwelling individuals aged 66 years and older who underwent one of five major elective surgeries between April 1, 2007 and March 31, 2011 were included. Each surgical patient was matched 1:1 on surgical specialty of the surgeon at consultation, age, sex, fiscal year of entry, and propensity score with a patient who attended an outpatient visit with a surgeon of the same surgical specialty but did not undergo surgery. Patients were followed for up to 5 years after cohort entry for the occurrence of a new dementia diagnosis, defined from administrative data. Cause-specific hazard models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for the association between surgery and the hazard of incident dementia. Subgroup and sensitivity analyses were performed.
RESULTS: A total of 27,878 individuals (13,939 matched pairs) were included in the analysis. A total of 640 (4.6%) individuals in the surgical group and 965 (6.9%) individuals in the control group developed dementia over the 5-year follow-up period. Individuals who underwent surgery had a reduced rate of incident dementia compared with their matched nonsurgical controls (HR 0.88; 95% CI 0.80-0.97; p = 0.01). This association was persistent in most subgroups and after sensitivity analyses.
CONCLUSIONS: Elective surgery did not increase the rate of incident dementia when compared with matched nonsurgical controls. This could be an important consideration for patients and surgeons when elective surgery is considered.
Patients reviewed at 6 weeks (+/- 1 week) as is our normal practice and recalled for a further evaluation if deemed appropriate. Patients will be instructed to visit their optometrist once their eye has fully recovered from the operation for provision of glasses.
The present invention provides for a novel, simplified method for preparing solid surfaces coated with water-soluble activated polyhydroxypolymers. The method entails contacting a solid surface which contains substantially no amino, imino, or thiol groups with a coating solution comprising an activated polyhydroxypolymer so as to obtain bonding of the activated polyhydroxypolymer to the solid surface, followed by rinsing and optionally drying of the solid surface. The contacting reaction must take place in an aqueous medium having a pH between 1.5 and 10 and or an ion strength between 0.1 and 8. Preferred polyhydroxypolymers are naturally occurring, aldehyde group-free polymers such as polysaccharides, especially dextran, but also cellulose, agarose and starch. Also synthetic polymers, especially polyvinylalcohol are preferred.  The water solubility of the polymer is preferably at least 10 mg/ml and its molecular weight is preferably at least 1,000. The activation of the polymer is preferably with functional groups selected from tresyl, maleimido, cyanogenbromide, tosyl, triflyl, pentafluorobenzenesulfonyl and vinylsulphone groups. Especially preferred activated polyhydroxypolymers are tresylated, tosylated, or maleimido activated dextran. The solid surface is preferably that of an organic polymer (such as polysterene) or of glass, a ceramic or a metal. Also provided is the solid surfaces obtainable by the process as well as of the use of the surfaces in the immobilisation of biomolecules.
The study was planned in randomized controlled experimental type. The pregnant women will be followed in single rooms. The information about how to apply the labor dance to the pregnant women in the experimental group will be explained by the researcher in the latent phase of birth and will be shown practically. Pregnant women in the experimental group will be given labor dance with music every hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. Pregnant women will musically choose one of Acemaşiran Authority, Rehavi Authority and Farid Farjad's Thin Rose of My Idea. The researcher and pregnant women will perform a labor dance with the music for 15 minutes per hour. The researcher and the pregnant will hold each other's hands (3-4 steps distance), stand opposite each other and perform pelvic tilt together. When the pregnant woman desires or has contractions, the researcher will massage the waist and sacrum area with a ball massage glove.

Details of the application and birth (such as dance time, birth time, contractions) will be recorded by the researcher. Pregnant women will be followed by the doctor, midwife and researcher during the tram, birth and first four hours postpartum.

Ball Massage Glove Used in Mechanical Massage Application It consists of nine metal balls with a diameter of 1.5 cm that can rotate 360 degrees. With its glove design and ergonomic structure, it can be easily applied to any area. By concentrating directly on the massage points, it can be used more effectively on all points of the body. Since it is made of silicone material, it does not harm the hand and the area to be massaged while massaging. (Information taken from introductory guide).
Patients receive ipilimumab IV over 90 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles for ipilimumab and up to 35 cycles for pembrolizumab in the absence of disease progression or unacceptable toxicity.